Press release: dupixent approved in the us as the first-ever biologic medicine for patients with copd

Dupixent approved in the us as the first-ever biologic medicine for patients with copd          dupixent is indicated for the approximately 300,000 adults in the us with inadequately controlled copd and an eosinophilic phenotype following recent approvals in the eu and china, the us approval is based on two landmark phase 3 studies that showed dupixent achieved significant reduction in exacerbations, and also showed improvements in lung function and health-related quality of life compared to placebo dupixent is the leading biologic medicine for all of its fda-approved indications in new-to-brand prescriptions, and the most prescribed biologic by pulmonologists in the us paris and tarrytown, ny, september 27, 2024. the us food and drug administration (fda) has approved dupixent (dupilumab) as an add-on maintenance treatment of adults with inadequately controlled chronic obstructive pulmonary disease (copd) and an eosinophilic phenotype.
REGN Ratings Summary
REGN Quant Ranking